News
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
10d
Tribune Content Agency on MSNA liquid biopsy for metastatic prostate cancerMetastatic prostate cancer can progress in different ways. In some men the disease advances rapidly, while other men have ...
Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...
Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...
Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...
4d
Medical Device Network on MSNASCO25: PanGIA Biotech’s AI-based urine test for prostate cancer hits trial successWith early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA ...
The longtime "SportsCenter" host plans to undergo surgery and is hoping to "normalize" the conversation about the illness.
5d
GlobalData on MSNASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drugJohnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...
The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...
A multiomic approach for detecting clinically significant prostate cancer in seminal fluid: Results from a large multicenter clinical study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Prostate cancer is the fourth most common cancer among men in India. Often symptomless in its early stages, it is highly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results